Banamine®
(flunixin meglumine paste)

Paste – 1500 mg
flunixin/syringe
Veterinary

For Oral Use in Horses Only

PRODUCT INFORMATION

CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION Each 30-g syringe of BANAMINE Paste contains flunixin meglumine equivalent to 1500 mg flunixin.

INDICATIONS BANAMINE Paste is recommended for the alleviation of inflammation and pain
associated with musculoskeletal disorders in the horse.

ACTIVITY Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-
inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and
codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity
occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of
activity is 24 to 36 hours.

CONTRAINDICATIONS There are no known contraindications to this drug when used as directed.

WARNING Do not use in horses intended for human consumption.

PRECAUTIONS The effect of BANAMINE Paste on pregnancy has not been determined. Studies to
date show there is no detrimental effect on stallion spermatogenesis with or following the
recommended dose of BANAMINE Paste.

SIDE EFFECTS During field studies with BANAMINE Paste, no significant side effects were
reported.

DOSAGE AND ADMINISTRATION The recommended dose of flunixin is 0.5 mg per lb of body
weight once daily. The BANAMINE Paste syringe, calibrated in twelve 250-lb weight increments,
delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse
once daily for 3 days, or three 1000-lb horses one time.

DOSAGE TABLE

<table>
<thead>
<tr>
<th>Syringe Mark*</th>
<th>Horse Weight (lbs)</th>
<th>BANAMINE Paste Delivered (g)</th>
<th>Mg Flunixin Delivered</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>250</td>
<td>250</td>
<td>2.5</td>
<td>125</td>
</tr>
<tr>
<td>500</td>
<td>500</td>
<td>5.0</td>
<td>250</td>
</tr>
<tr>
<td>750</td>
<td>750</td>
<td>7.5</td>
<td>375</td>
</tr>
<tr>
<td>1000</td>
<td>1000</td>
<td>10.0</td>
<td>500</td>
</tr>
</tbody>
</table>

* Use dial edge nearest syringe barrel to mark dose.
The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of BANAMINE Solution, followed by BANAMINE Granules or BANAMINE Paste on Days 2 to 5. BANAMINE treatment should not exceed 5 consecutive days.

**TOXICITY** No toxic effects were observed in rats given oral flunixin 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for fifteen consecutive days.

**HOW SUPPLIED** BANAMINE Paste, 1500 mg is available in a single 30-g syringe.

Store below 25°C (77°F). Do not Freeze.


**PRINCIPAL DISPLAY PANEL - 1500 mg Syringe Label**

Syringe contains flunixin meglumine equivalent to

1500 mg

FLUNIXIN
Net Wt 30 g

NDC 0061-0214-02

Banamine®
(flunixin meglumine paste)
Paste

For oral use in horses only.
Warning: Do not use in horses intended for human consumption.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under NADA # 137-409

MERCK
Animal Health
**BANAMINE**
flunixin meglumine paste

**Product Information**

- **Product Type**: PRESCRIPTION ANIMAL DRUG
- **Route of Administration**: ORAL

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flunixin Meglumine (UNII: 8Y3JK0JW3U) (Flunixin - UNII:356IB1O400)</td>
<td>Flunixin</td>
<td>1500 mg in 1 g</td>
</tr>
</tbody>
</table>

**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch, Corn (UNII: O8232NY3SJ)</td>
<td></td>
</tr>
<tr>
<td>Propylene Glycol (UNII: 6DC9Q167V3)</td>
<td></td>
</tr>
<tr>
<td>Carboxymethylcellulose (UNII: 05JZI7B19X)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
</tbody>
</table>
### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0061-0214-02</td>
<td>30 g in 1 SYRINGE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NADA</td>
<td>NADA137409</td>
<td>11/11/2011</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Merck Sharp & Dohme Corp. (001317601)

Revised: 9/2019